The company’s experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug ...
The approach is still experimental, but a newly approved drug, advances in early detection, and promising research involving ...
Allegheny Health Network's Cancer Center contributed thousands of tests to an international pancreatic cancer research ...
Prior to final Food and Drug Administration approval in August, UH, MetroHealth and the Cleveland Clinic gained access to the ...
A 20-year analysis of national cancer registry data finds localized pancreatic cancer diagnoses rising sharply, especially ...
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
Exactly what causes pancreatic cancer has long remained a mystery. But one scientist who has studied the disease for more ...
Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, ...
Propanc Biopharma, Inc. , a biopharmaceutical company, highlighted new preclinical data for its lead investigational candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results